# Helus Pharma Advances Mental Health Treatments

> Helus Pharma reports progress on two mental health drugs for depression and anxiety.
- Title: Helus Pharma Advances Mental Health Treatments · Financialpost
- Summary: Helus Pharma reports progress on two mental health drugs for depression and anxiety. Helus Pharma's HLP003 and HLP004 programs show progress in clinical…
- Keywords: helus pharma, hlp003, hlp004, mdd, gad, phase 3, phase 2, money, business, Helus, Pharma, Advances
- Source: Financialpost — https://financialpost.com/globe-newswire/helus-pharma-highlights-clinical-program-advancements-at-investor-presentation-held-on-october-21-2026
- Read time: 1 min
- Topics: helus pharma, hlp003, hlp004, mdd, gad, phase 3, phase 2, money, business
## Helus Pharma Investor Presentation
Helus Pharma held an investor presentation on October 21, 2026.
## HLP003 Phase 3 Study
HLP003's APPROACH Phase 3 topline data readout is on track for Q4 2026.
## HLP004 Phase 2 Study
HLP004's Phase 2 monotherapy study for generalized anxiety disorder starts in Q1 2027.
## FDA Breakthrough Designation
HLP003 has FDA Breakthrough Therapy Designation for expedited review.
## CEO Statement
CEO Michael Halstead says Helus Pharma is focused on regulatory approval and commercialization.
## Next Steps
Helus Pharma expects to file a New Drug Application with the FDA in 2028.
## Key takeaway

Helus Pharma's HLP003 and HLP004 programs show progress in clinical trials for depression and anxiety treatments.